Hims & Hers caused a firestorm last week when it revealed that it planned to launch a knockoff version of Novo Nordisk's new ...

Large drugmakers once had more room to absorb failure, both financially and reputationally | Large drugmakers are facing tighter constraints than in the past, as financial, scientific and reputational ...

With online health and wellness company Hims & Hers opening a new front in the GLP-1 compounding showdown Thursday, the ...

With an oversubscribed trading debut now in the books, Veradermics—developing an oral version of the molecule behind ...

Novartis CEO Vas Narasimhan is doubling down on a growth forecast for 2026, even as the Swiss drugmaker’s fourth-quarter ...

The campaign highlights the crossover that Lilly sees between its own 150 years of working toward scientific progress and the ...

Amid the fast-moving rollout of the Wegovy pill, Novo Nordisk has taken to advertising’s biggest stage to help get the word ...

To stir up support for the fight against cancer, Pfizer has turned to one of the most iconic pep talks of all time. | To stir ...

Amgen has denied a request by the FDA to voluntarily withdraw its rare disease drug Tavneos from the market, the company said ...

After a brief delay last month, another piece of the Trump administration’s healthcare policy has fallen into place. | ...

After Novo Nordisk projected yesterday that its revenue could decline by as much as 13% in 2026, its share price has ...

Biogen recorded declining sales for Spinraza in each of the four quarters of 2025, but the Massachusetts drugmaker sees ...